Format

Send to

Choose Destination
Urol J. 2019 Jan 13. doi: 10.22037/uj.v0i0.4497. [Epub ahead of print]

The effect of time to castration resistance on overall survival and success of docetaxel treatment in castration resistant prostate cancer patients.

Author information

1
Ankara University School of Medicine, Department of Urology, Ankara, TURKEY. drevrensuer@gmail.com.
2
Ankara Atatürk Research and Training Hospital, Department of Urology, Ankara, TURKEY.
3
Ankara University School of Medicine, Department of Urology, Ankara, TURKEY.

Abstract

INTRODUCTION:

To investigate the prognostic role of time to castration resistance(TTCR) in patients who have received solely Docetaxel chemotherapy regimen(DCR) for castration resistant prostate cancer(CRPC). Methods: Between Jan 2004 and Dec 2015, data of 162 patients who have received DCR for CRPC are detected. Patients were divided into three groups according to TTCR: Group 1(?12 months), group 2(13-24 months), and group 3(>24 months). Data of age, clinical stage, Gleason grade(GG), previous treatments, site of metastases, Prostate-specific antigen (PSA) values, TTCR, overall survival, biochemical progression free survival(PFS) and PSA response to docetaxel were recorded.

RESULT:

The mean age of the 162 patients was 74.4±8.5. Data on mean age, type of castration, adding estramustine to docetaxel, secondary hormonal manipulation, Gleason grade, clinical T stage at initial diagnosis and site of metastases were comparable between three groups. All PSA values were statistically significant higher in group 1 than other groups. PSA response to docetaxel was 59.2% in all patient and it was worse in group 1 than other groups(P=.009). Two years OS rates were 7.6%, 25% and 32.3% in group 1, 2 and 3, respectively. Median survival rates were 7, 14 and 23 months in group 1, 2 and 3, respectively, and this difference was statistically significant (P=.016). On multivariate analysis, TTCR was found to be independent prognostic factor for overall survival and response to docetaxel treatment.

CONCLUSION:

TTCR appears to be an independent prognostic factor for patients who are candidates for DCR.

PMID:
30636274
DOI:
10.22037/uj.v0i0.4497
Free full text

Supplemental Content

Full text links

Icon for Urology and Nephrology Research Center
Loading ...
Support Center